Roche

Novel therapies and regulatory shifts drive growth in the Duchenne muscular dystrophy market, with exon-skipping therapies leading…

The decision, made in response to Roche's appeal on October 16, 2024, reversed an earlier order from October 9, 2024

GlobalData reports the rise in HER2+ breast cancer cases, stressing the importance of cost-effective biosimilars as Zydus and…

The data showcases Vabysmo’s efficacy in wet age-related macular degeneration (wAMD) and diabetic macular edema (DME)

GlobalData’s patient-based forecast reveals that the BRAF inhibitor market for melanoma will reach a key milestone by 2028, with…

If approved, glofitamab would be the first fixed-duration CD20xCD3 T-cell engaging bi-specific antibody approved to treat the most…

The drug, known chemically as mosunetuzumab, can be administered at a hospital’s outpatient centre, unlike some other follicular…

The company will propose Severin Schwan as the new Chairman at the Annual General Meeting in 2023

Updated data from phase-III Polarix study continue to demonstrate a statistically significant reduction in the risk of disease…

The Swiss drugmaker conducted two identically designed studies, each with about 1,000 participants, who were examined and queried…